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Carbapenemase-producing Enterobacteriaceae (CPE) 
strains have been increasingly reported in Belgium. 
We aimed to determine the proportion of CPE among 
Enterobacteriaceae isolated from hospitalised patients 
and community outpatients in Belgium in 2015. For 
the hospitalised patients, the results were compared 
to a previous similar survey performed in the same 
hospitals in 2012. Twenty-four hospital-based and 10 
private laboratories collected prospectively 200 non-
duplicated Enterobacteriaceae isolates from clinical 
specimens. All isolates were screened locally by car-
bapenem disk diffusion using European Committee 
on Antimicrobial Susceptibility Testing methodology. 
Putative CPE strains with inhibition zone diameters 
below the screening breakpoints were referred cen-
trally for confirmation of carbapenemase produc-
tion. From September to November 2015, we found a 
proportion of clinical CPE of 0.55% (26/4,705) and of 
0.60% (12/1,991) among hospitalised patients and 
among ambulatory outpatients respectively. Klebsiella 
pneumoniae (26/38) and OXA-48-like carbapenemase 
(28/38) were the predominant species and enzyme 
among CPE. One OXA-48-producing Escherichia coli 
isolated from a hospital was found carrying plasmid-
mediated MCR-1 colistin resistance. Compared with 
the 2012 survey, we found a significant increased 
proportion of clinical CPE (0.55% in 2015 vs 0.25% in 
2012; p = 0.02) and an increased proportion of hospi-
tals (13/24 in 2015 vs 8/24 in 2012) with at least one 
CPE detected. The study results confirmed the con-
cerning spread of CPE including a colistin-resistant 
MCR-1 producer in hospitals and the establishment of 
CPE in the community in Belgium.
Introduction
Acquired carbapenemases in Enterobacteriaceae have 
been reported extensively worldwide [1]. Asymptomatic 
carriage and infection caused by carbapenemase-
producing Enterobacteriaceae (CPE) isolates currently 
raise major public health concern for individual thera-
peutic management and for collective infection con-
trol [2]. The prevalence of carbapenem resistance and 
the types of carbapenemases found in Europe vary 
between countries [3,4] and since 2010 an increase 
in the isolation rate of CPE from various European 
countries has been reported [5]. In Belgium, the last 
multicentric survey performed among 24 hospitals 
in 2012 [6] showed an overall proportion of 3.5% 
of carbapenem non-susceptible Enterobacteriaceae 
(CNSE) and an estimated proportion of 0.28% of CPE 
among Enterobacteriaceae isolates using Clinical and 
Laboratory Standards Institute (CLSI) carbapenems 
susceptibility breakpoints as screening criteria [7]. 
Further, one third (8/24) of the participating hospital 
laboratories had isolated one or several CPE isolates 
in their institution during the study period [6]. The 
national surveillance programme of CPE established in 
January 2012 by the Scientific Public Health Institute 
together with the National Reference Centre showed a 
yearly increase from 2012 to 2014 of number and pro-
portion of hospital-based and of private laboratories 
reporting confirmed CPE [8].
The present cross-sectional survey aimed to determine 
the evolution of the proportion of CNSE and of CPE 
among Enterobacteriaceae isolates collected in Belgian 
hospitals and to gain insight of their epidemiology 
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outside hospitals in specimens collected from commu-
nity outpatients sent to private laboratories.
Methods
Study design, inclusion criteria and testing at 
participating centres
In 2015, 24 hospital-based laboratories that partici-
pated to the survey in 2012 serving around 25% of all 
acute hospitals in Belgium (hospital size ranging from 
288 to 1,803 beds; median number of 747 beds per 
hospital) were requested to collect consecutively 200 
Enterobacteriaceae isolates cultured from clinical sam-
ples of hospitalised patients (screening samples such 
as stools or rectal swabs were excluded) over a period 
of 2 months (i.e. from September to November). Only 
the first isolate of the same species per patient was 
included. The sample collection, culture and bacterial 
identification were performed using local procedures. 
In addition, 10 private laboratories (representing 
around 20% of all private laboratories in Belgium) 
serving general practitioners participated as well using 
the same study protocol and were asked to test 200 
Enterobacteriaceae isolates cultured from clinical sam-
ples of outpatients in the community.
All isolates were tested locally for susceptibility to 
meropenem (10-µg) and ertapenem (10-µg) by disk 
diffusion method according to European Committee 
on Antimicrobial Susceptibility Testing (EUCAST) 
guidelines [9] and all inhibition zone diameters were 
recorded. All testing materials purchased from the 
same manufacturer (BioRad, Marnes-la-Coquette, 
France) had the same manufacture batch number in 
order to avoid inter-lot variations. Escherichia coli ATCC 
25922 was tested as quality control strain in each cen-
tre during the survey.
Enterobacteriaceae isolates showing a decreased inhi-
bition zone diameters according to EUCAST screening 
breakpoints [10] to any of the two carbapenems disks 
(ertapenem < 25 mm and/or meropenem < 25 mm) were 
defined as putative CPE (PCPE) and had to be referred 
to the reference laboratory.
Characterisation of resistance mechanisms and 
data analysis
All PCPE isolates sent to the reference laboratory were 
tested for carbapenemase production by the electro-
chemical imipenem-hydrolysis based BYG Carba test 
[11] and underwent multiplex PCR targeting blaVIM, 
blaIMP, blaNDM, blaKPC and blaOXA-48 for the detec-
tion of carbapenemase encoding genes [12]. The PCR-
positive amplicons were sequenced using an external 
service company (Macrogen Inc., Seoul, South Korea). 
The sequence obtained was compared with the genes 
Table 1
Species/group distribution and proportion of CNSE (according to EUCAST interpretative criteria) and of CPE among 
isolates screened by 24 hospital-based and 10 private community-serving laboratories in Belgium, 2012 (n = 4,471) and 2015 
(n = 6,696)
Species or group
2015 survey 2012 survey
Screened CNSE %CNSE CPE %CPE Screened CNSE %CNSE CPE %CPE
Hospital-based laboratory
Escherichia coli 2,560 15 0.6 3 0.12 2,537 26 1.0 1 0.04
Klebsiella pneumoniae 629 35 5.6 18 2.86 434 36 8.3 9 2.07
Klebsiella oxytoca 216 3 1.4 2 0.93 209 3 1.4 1 0.48
Citrobacter spp. 150 7 4.7 3 2.00 150 11 7.3 0 0
Enterobacter spp. 423 61 14.4 0 0 391 118 30.2 0 0
Proteaceae 551 7 1.3 0 0 559 15 2.7 0 0
Others 176 1 0.6 0 0 191 7 3.7 0 0
Total 4,705 129 2.7 26 0.55 4,471 216 4.8 11 0.25 
Private community-serving laboratorya
Escherichia coli 1,276 3 0.2 1 0.08
Not available
Klebsiella pneumoniae 275 19 6.9 8 2.91
Klebsiella oxytoca 73 3 4.1 1 1.37
Citrobacter spp. 71 2 2.8 2 2.82
Enterobacter spp. 81 10 12.3 0 0
Proteaceae 184 0 0 0 0
Others 31 0 0 0 0
Total 1,991 37 1.9 12 0.60 
CNSE: carbapenem-non-susceptible Enterobacteriaceae; CPE, carbapenemase-producing Enterobacteriaceae; EUCAST: European Committee on 
Antimicrobial Susceptibility Testing.
a Private laboratories served general practitioners for outpatient care.
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present in GenBank and aligned with the reference 
gene cited at the Lahey Clinic [13]. 
For confirmed CPE isolates, minimal inhibitory concen-
tration (MIC) values of antimicrobial agents including 
carbapenems were determined by broth microdilution 
method (Sensititre, Trek Diagnostic Systems, Cleveland, 
US). The MIC value of temocillin was determined by 
Etest method (bioMérieux, Marcy-l’Etoile, France). 
Susceptibility categorisation was interpreted according 
to EUCAST interpretative criteria [9] for all antimicro-
bial agents except temocillin (breakpoints according 
to Fuchs et al.) [14]. Colistin-resistant isolates were 
further tested by end-point PCR for the presence of the 
plasmid-mediated colistin resistance mcr-1 gene [15].
The proportion of CNSE as defined by the EUCAST disk 
diffusion susceptibility breakpoints (ertapenem <25 
mm and/or meropenem <22 mm) and of CPE isolates 
were calculated based on inhibition zone diameters of 
all isolates provided overall in hospitals or in private 
laboratories, for each centre and also by species or 
genus. Following the application of harmonised micro-
biological criteria (the ertapenem and meropenem 
discs zone diameters recorded in 2012 were reinter-
preted using EUCAST interpretative criteria), results 
from 2015 were compared with those in 2012 for hospi-
tal-based laboratories.
Clonal relatedness of the carbapenemase-producing 
Klebsiella pneumoniae isolates was investigated by the 
DiversiLab system (bioMérieux, Marcy l’Étoile, France) 
using the repetitive extragenic palindromic (rep)-PCR 
methodology [16]. Isolates with > 95% similarity were 
considered related.
Results
In total, 4,705 and 1,991 non-duplicate 
Enterobacteriaceae isolates were screened by the 24 
hospital-based and by 10 private laboratories respec-
tively from September to November 2015. A median 
number of 200 isolates per laboratory was achieved 
and all but one centre reached > 195 isolates screened. 
The distributions of origins of screened isolates were 
highly comparable to 2012 with urine (2,642/4,705; 
56%) and medical wards (1,818/4,705; 39%) represent-
ing the principal origins of the isolates screened and 
the main sources of CNSE isolates in hospitals (data 
not shown). The highest proportion of CNSE isolates 
in hospitals was found in respiratory tract (36/714; 
5.0%) and in the intensive care units (30/711; 4.2%). 
On the other hand, urinary origin (1,902/1,991; 96%) 
of screened isolates was as expected largely predomi-
nant in private laboratories.
The number and the proportions of CNSE according to 
EUCAST susceptibility criteria and of CPE among tested 
isolates per species are reported and compared with 
the 2012 study results in Table 1.
The global proportion of CNSE among clinical 
Enterobacteriaceae isolates among hospitalised 
patients in 2015 was 2.7% (129/4,705; 95% confidence 
interval (CI): 2.3–3.2%) and it ranged per centre from 
0.5% (1/200) to 7.0% (14/200). Compared with the 
2012 results calculated after using identical microbio-
logical criteria (216/4,471; 4.8%; 95% CI: 4.2–5.4%), 
the overall proportion of clinical CNSE decreased sig-
nificantly in the same hospitals (p < 0.001 by Pearson 
chi-squared test). While the proportion of Enterobacter 
spp. among screened isolates in hospitals were identi-
cal between the two study periods (i.e. 9%; 423/4,705 
in 2015 and 391/4,471 in 2012), the carbapenem non-
susceptibility rate dropped significantly in this group 
from 30.2% (118/391) in 2012 to 14.4% (61/423) in 2015 
(p < 0.001) and contributed to the overall decrease of 
the CNSE rate in 2015. 
Among ambulant patients, a total of 37 isolates from 
seven private laboratories would be categorised as 
Table 2
Carbapenemase types detected in clinical CPE isolates per 
health centre, Belgium, 2012 (n = 11 CPE isolates) and 2015 
(n = 38 CPE isolates)
Centre 
numbers
Carbapenemase (number of isolates)
2015 survey (38) 2012 survey (11)
Hospital-based laboratory
C02 OXA-48 (1) None
C04 None KPC (1)
C06 OXA-48 (2) OXA-48 (1)
C07 NDM-1 (1) None
C08 NDM-5 and OXA-181 (1), OXA-48 (1) OXA-48 (1)
C10 OXA-48 (1) None
C11 OXA-48 (2) None
C12 NDM-1 (1) KPC (1)
C13 OXA-48 (2) OXA-48 (1)
C14 KPC-2 (1), KPC-3 (1) KPC (2), NDM (1)
C17 OXA-48 (4) None
C19 None OXA-48 (1)
C20 OXA-48 (1) None
C23 KPC-3 (3), KPC-2 (1), VIM-1 (1) OXA-48 (2)
C24 OXA-48 (2) None
C01, C03, 
C05, C09, 
C15, C16, 
C18, C21, 
C22
None None
Private community-serving laboratorya
C26 OXA-48 (4)
Not available
C30 OXA-48 (6)
C33 OXA-48 (1), KPC-3 (1)
C25, C27, 
C28, 
C29, C31, 
C32, C34
None
CPE: carbapenemase-producing Enterobacteriaceae.
a Private laboratories served general practitioners for outpatient 
care.
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CNSE representing a proportion of clinical CNSE isolates 
of 1.9% (37/1,991; 95% CI: 1.3%–2.5%) in the ambula-
tory setting ranging per centre from 0% to 8% (16/200). 
Comparing to the hospitals in which Enterobacter spp. 
accounted for nearly half of the CNSE isolates (61/129), 
K. pneumoniae represented the main CNSE species 
among the ambulatory isolates (19/37) since a lower 
proportion of Enterobacter spp. (4%; 81/1,991) were cul-
tured in private laboratories. In hospitalised patients, 
the rate of meropenem non-susceptibility found in K. 
pneumoniae (2.5%; 16/629) remained stable in 2015 
compared with 2012 (2.3%; 10/434).
Overall in 2015, 114/133 (86%) and 30/42 (71%) PCPE 
(using EUCAST screening cut-offs) isolates were 
referred from hospital-based and from private laborato-
ries respectively to the reference laboratory and tested 
for the presence of carbapenemase. Considering the 
hospital-based and private laboratory data together, 
K. pneumoniae (26/38; 68%) and OXA-48 (28/38; 
74%) were the main species and carbapenemase type 
respectively detected among CPE isolates in Belgium. 
While none of the 57 Enterobacter spp. isolates ana-
lysed could be confirmed as CPE, nearly half of the 
referred K. pneumoniae isolates (26/54; 48%) were 
confirmed as CPE (OXA-48-like, n = 17; KPC-type, n = 7; 
and NDM-type, n = 2). OXA-48 carbapenemase was 
detected in four E. coli isolates including one copro-
ducing NDM enzyme, three Citrobacter freundii, two C. 
koseri and two K. oxytoca isolates. One VIM-producing 
K. oxytoca was also detected by PCR. All PCR-negative 
PCPE isolates did not hydrolyse imipenem by BYG 
Carba test, thus excluding the phenotypical expression 
of undetected carbapenemases by our multiplex PCR 
assay.
On the whole, the minimal estimated proportion of 
CPE was 0.55% (26/4,705; 95% CI: 0.34–0.76%) among 
clinical Enterobacteriaceae isolated from hospitalised 
patients and 0.60% (12/1,991; 95% CI: 0.26–0.94%) 
among the ambulatory patients ranging per centre from 
0% (for 11 hospitals and seven private laboratories) to 
3.09% (6/194; in one centre). The distribution of car-
bapenemase types by centre is listed in Table 2.
In 2015 among hospitals, while the 16 cases of OXA-
48 CPE were distributed in nine different hospitals, the 
6 KPC-type CPE cases were grouped within two hos-
pitals. In the community setting, the 12 CPE isolates 
(dominated by OXA-48; n = 11) were found in isolates 
from three private laboratories. 
Compared with 2012 (11/4,471, 0.25%; 95% CI: 0.10–
0.39%), the overall proportion of clinical CPE in 2015 
(26/4,705, 0.55%; 95% CI: 0.34–0.76%) increased sig-
nificantly (p = 0.02 by Pearson chi-squared test) in the 
24 surveyed hospitals and the proportion of hospitals 
collecting at least one clinical CPE isolate also appears 
to have increased from 8/24 in 2012 to 13/24 in 2015 (p 
value non-significant).
Based on disc diffusion with EUCAST interpretative 
criteria, all 38 confirmed CPE isolates in 2015 were 
intermediately-resistant or resistant to ertapenem 
disk while 16 (42%; all of OXA-48 type) were catego-
rised as susceptible to meropenem disk. Two OXA-48-
producing (one E. coli and one C. koseri) isolates had 
an inhibition zone to meropenem of ≥ 25 mm and would 
be missed if EUCAST screening breakpoint was applied 
using meropenem disc alone. One of these two CPE (C. 
koseri) showed additionally an ertapenem zone diame-
ter of 24 mm and therefore would have been missed as 
well if the CLSI susceptibility breakpoints (ertapenem 
<22 mm and/or meropenem <23 mm) used as screening 
criteria in the 2012 survey were applied.
Origins and microbiological characteristics includ-
ing MIC results of the 38 confirmed CPE isolates are 
detailed in Table 3.
On the basis of MIC using EUCAST interpretative crite-
ria, only two (5%; one VIM-producing K. oxytoca and 
one OXA-48-producing C. koseri) isolates were sus-
ceptible to ertapenem (MIC ≤1 µg/mL), while 23 (61%) 
OXA-48-positive isolates had imipenem and/or mero-
penem MICs within the susceptible range (MIC ≤2 µg/
mL). All CPE isolates were found resistant to pipera-
cillin/tazobactam and to temocillin with higher temo-
cillin MIC levels (≥ 256 µg/mL) for OXA-48 and VIM 
producers compared with more variable MIC levels 
(24–1,024 µg/mL) for KPC- and for NDM-positive iso-
lates. Ceftolozane/tazobactam showed poor activity 
against CPE since only eight (21%) OXA-48 producers 
had MIC below the susceptibility cut-off (≤ 1 µg/mL). 
Tigecycline retained the highest in vitro activity (MIC 
≤1 µg/mL) against 95% (36/38) of CPE followed by 
colistin (MIC ≤2 µg/mL), which was active against 82% 
(31/38) of the CPE. Interestingly of the seven colistin-
resistant CPE isolates in 2015, which were all collected 
from hospitals (only one detected in the 2012 survey), 
one OXA-48-positive E. coli was found positive for the 
plasmid-mediated mcr-1 gene.
Molecular typing by rep-PCR of the 26 carbapene-
mase-producing K. pneumoniae isolates showed their 
belonging to 19 different DiversiLab (DL) patterns with 
four clusters (DL types 3, 5, 16 and 23) of more than 
one isolates (Table 3). The three DL type 16 KPC-3 pro-
ducing isolates were detected in centre C23 and the 
three DL type 23 OXA-48 producing isolates in centre 
C17. The other DL types 3 and 5 (all OXA-48 producing) 
isolates were found in two (one hospital-based and 
one community-serving) centres each.
Discussion
In this multicentric 2015 survey, we found an over-
all doubling proportion of 0.55% of clinical CPE 
among Enterobacteriaceae isolates in hospitals com-
pared with 2012 (0.25%). The microbiological analy-
sis confirmed the predominance of K. pneumoniae 
and of OXA-48 among CPE isolates in hospitals and 
in the community in Belgium. Molecular typing of 
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carbapenemase-producing K. pneumoniae confirmed 
mostly polyclonal distribution although clusters of 
identical DL types with suspected clonal spread were 
highlighted as well. Two clusters of different DL types 
(16 and 23) strongly suggested their intra-hospital 
clonal dissemination or outbreak. Additionally, the 
presence of other OXA-48 producing DL types (3 and 
5) both in hospitals and in private laboratories that 
are geographically close (distance < 30 km) raised the 
possibility of epidemiological links between the two 
healthcare sectors. Although no patient history regard-
ing travel or hospitalisation in foreign country was 
available in this study, data from the national surveil-
lance programme and from the previous prevalence 
study in 2012 support that the proportion of travel-
imported CPE cases should be limited [17].
The strength of our study relies on the use of a stand-
ardised methodology performed within the same hos-
pitals between the two study periods to measure the 
epidemiological parameters with minimal variations 
due to technical inter-laboratory variability or samples 
selection bias. The 24 hospital-based laboratories 
serving tertiary care and general acute-care hospitals 
of medium to large size were selected for their repre-
sentative distribution in the three geographical regions 
(Flanders, Brussels and Wallonia) across Belgium. Only 
strains isolated from clinical samples were included 
in the studies in order to limit recruitment bias due to 
variations in screening strategies for CPE between hos-
pitals. However, our study has some limitations. First, 
18% (31/175) of the PCPE isolates detected locally were 
not referred to the reference laboratory suggesting that 
the proportion of CPE of 0.55% should be considered 
as a minimal estimate. Also, the higher proportion of 
CPE in hospitals in 2015 compared to 2012 could result 
from the use of EUCAST screening breakpoints theo-
retically more sensitive than the CLSI susceptibility cri-
teria applied in 2012. In spite of this, the fact that in 
the present study, only one OXA-48 producing C. koseri 
had the two carbapenems inhibition zones above the 
CLSI susceptibility cut-offs suggests very rare occur-
rence of these CPE isolates that poorly expressed 
carbapenemases.
In addition, the higher proportion of colistin resistance 
among CPE strains detected in hospitals corroborates 
with the phenomenon of increasing colistin resistance 
among CPE isolates observed in Belgium and else-
where for the past years [18,19]. Furthermore the study 
evidenced the emergence of the first human MCR-1-
positive CPE in Belgian hospitals as well, similar other 
countries worldwide, where this has also been recently 
reported in healthcare [20-22].
In Spain, the latest prospective multicentric study in 83 
hospitals performed in 2013 reported a similar overall 
estimated prevalence of 0.3% of CPE [4] (higher than 
the 0.04% of metallo-beta-lactamase-producing CPE 
detected in the previous 35-centres survey in 2009) 
[23], but 20% of the CPE were of faecal screening origin. 
The survey showed the same predominance of OXA-48 
type CPE, but VIM-producing isolates (the second most 
frequent) were more widely geographically distributed. 
Sporadic community-onset infection and post-travel 
acquisition of CPE had been reported in western coun-
tries [24-26]. In 2016 a case report in Belgium described 
a household acquisition of OXA-48 producing K. pneu-
moniae in a woman living in the same household than 
a patient previously infected with a similar CPE, raising 
the possibility of community spread in low-prevalence 
areas [27]. However to our knowledge, no specific pro-
spective cross-sectional survey addressing clinical iso-
lates in an ambulatory setting has yet been published.
Regarding the smaller proportion of CNSE (mainly due 
to the significant decreasing proportion of CNSE among 
Enterobacter spp.) in hospitals in 2015 compared with 
2012, no clear explanation could be found. However, a 
cluster effect could be excluded since the decreased 
rate of CNSE was documented in 18 of the 24 partici-
pating hospitals (data not shown).
In conclusion, this multicentric survey demonstrated a 
significantly increased proportion of CPE among clinical 
Enterobacteriaceae isolates in hospitals from 2012 to 
2015 with an increased proportion of hospitals-based 
laboratories detecting at least one CPE. Although the 
proportion of CPE remained globally low, the steady 
progression and spread of CPE in Belgian hospitals 
and the emergence of colistin-resistant (including 
plasmid-mediated mcr-1 harbouring) strains among 
CPE raises major concerns. In parallel, the survey in 10 
private laboratories highlighted for the first time the 
establishment of CPE (mainly K. pneumoniae species 
and of OXA-48 type) in an ambulatory setting and sug-
gested possible epidemiological links with hospitals. 
We therefore believe that repeated national or regional 
epidemiological studies using standardised protocols 
at different healthcare levels are essential to measure 
more accurately the burden of carbapenem resistance.
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